- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million –– Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million –STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]
As you might know, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) just kicked off its latest third-quarter results with...
Image source: The Motley Fool. Collegium Pharmaceutical Inc (NASDAQ: COLL)Q3 2020 Earnings CallNov 6, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
– Strengthened Formulary Access for Xtampza® ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations –– Adjusted EBITDA of $41.8 Million –– Conference Call Scheduled for Today at 4:30 p.m. ET –STOUGHTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter end...
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Collegium Pharmaceutical, Inc.